For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Before You Checkout
Bundle complementary compounds together — priced below buying each separately.
Bremelanotide, a cyclic heptapeptide melanocortin receptor agonist with binding activity at MC3R and MC4R. Investigated in preclinical research for melanocortin system signaling, central nervous system receptor activation, and downstream neuroendocrine pathway characterization.
Dosage
10mg
Form
Lyophilized Powder
Bundle & Save
$34.95
Quantity
Research Application Guidelines
This research compound is designed exclusively for controlled in vitro studies carried out by trained professionals. It is not intended for human or animal use and must not be incorporated into foods, cosmetics, medications, or diagnostic processes.
Regulatory Notice
This material has not been evaluated by the FDA and is not sold for the purpose of diagnosing, treating, curing, or preventing any condition. All handling, storage, and research use must comply with applicable regulations and institutional requirements.
Purchase & Responsibility Agreement
By purchasing from Ascension Labs, the buyer confirms that they are a qualified researcher or authorized laboratory. All sales are final. The buyer assumes full responsibility for the proper handling, storage, usage, and regulatory compliance of this material.
What's Included
Storage Guidelines
Quality Assurance
Disclaimer: Our peptides are research-grade products for laboratory use only. They are not approved for human consumption or medical use. Always follow proper laboratory safety protocols.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin-receptor agonist with activity at MC3R and MC4R. It is studied in vitro for central melanocortin signaling and neuroendocrine pathways.
Also referred to as: Bremelanotide, PT141, melanocortin agonist.
PT-141, known as bremelanotide, is a cyclic heptapeptide studied as an agonist at melanocortin receptors MC3R and MC4R. In laboratory models, receptor activation is examined through central melanocortin signaling and downstream neuroendocrine pathways. Cell-based cAMP assays are used to characterize its receptor engagement, keeping all observations within non-human, mechanism-focused research contexts.
Bremelanotide is a synthetic cyclic heptapeptide of the melanocortin-agonist class. Its structure is closely related to melanocortin analogs but terminates in a free carboxylic acid rather than an amide. This cyclic seven-residue architecture is the defining identity used in research characterization, and the material is handled as a lyophilized peptide powder.
Both are cyclic melanocortin peptides, but in comparative studies PT-141, a free-acid heptapeptide, is oriented toward MC3R and MC4R signaling, with little of the MC1R-driven melanogenesis activity emphasized for MT-2. This selectivity difference is characterized in receptor-binding assays and makes PT-141 a tool for studying central melanocortin pathways specifically.
Yes. Every batch of PT-141 is independently tested by HPLC and mass spectrometry, and ships with a lot-specific Certificate of Analysis verifying 99.1% purity and molecular identity.
Store lyophilized PT-141 at -20°C for long-term storage or 2-8°C short-term. After reconstitution, keep refrigerated at 2-8°C and avoid repeated freeze-thaw cycles.
No. PT-141 is sold strictly for in-vitro research and laboratory use only. It is not a drug or supplement and is not intended for human or animal consumption.